Aytu Biopharma, INC 8-K filings

Aytu BioPharma and Lannett Company have mutually agreed to terminate their exclusive license agreement for Metadate CD effective June 23, 2026.

Aytu BioPharma announced its fiscal 2026 third quarter results, reporting $12.4 million in net revenue, a decrease from the prior year, with new drug EXXUA contributing $2.4 million.

Aytu BioPharma has amended outstanding warrants to clarify beneficial ownership blockers, aiming to reclassify warrant liabilities as equity.

Aytu BioPharma reports fiscal Q2 2026 results with decreased net revenue and a significant net loss, alongside the commercial launch of its new MDD treatment, EXXUA.

Aytu BioPharma recapped its Investor Day, focusing on the commercial launch and market opportunity for EXXUA, its novel antidepressant for Major Depressive Disorder.

Aytu BioPharma, Inc. announced the results of its 2026 annual meeting, where stockholders re-elected all incumbent directors, ratified Grant Thornton LLP as its independent auditor, and approved executive compensation.

Aytu BioPharma announced its fiscal 2026 first quarter operational and financial results, confirming the EXXUA launch remains on track for the fourth calendar quarter of 2025.

Aytu BioPharma announced its fiscal 2025 full year and fourth quarter results, alongside plans for the commercial launch of EXXUA in the fourth calendar quarter of 2025, targeting the major depressive disorder market.

Aytu BioPharma, Inc. has terminated its Asset Purchase Agreement for AR101, transferring all rights to EnzCo, LLC with no remaining obligations.

Aytu BioPharma has successfully expanded and extended its lending agreement with Eclipse Business Capital LLC, increasing its term loan to $13.0 million and adding a $1.5 million incremental revolving advance, providing crucial working capital flexibility ahead of the EXXUA commercial launch.

Aytu BioPharma, Inc. announced it has posted an updated investor presentation to its website, which will be used for upcoming investor meetings and highlights the EXXUA (gepirone) extended-release tablets opportunity.

Aytu BioPharma announced the closing of an upsized public offering raising $16.6 million, with proceeds earmarked for the commercialization of EXXUA, its first-in-class antidepressant expected to launch in Q4 2025.

Aytu BioPharma, Inc. announced the pricing of an upsized public offering of common stock and prefunded warrants, raising approximately $14.4 million to fund general corporate purposes and the exclusive commercialization of EXXUA.

Aytu BioPharma has entered into an exclusive agreement with Fabre-Kramer Holdings, Inc. to commercialize EXXUA, a first-in-class, FDA-approved treatment for Major Depressive Disorder, targeting the substantial $22 billion U.S. prescription MDD market.

Aytu BioPharma's stockholders approved an amendment to the 2023 Equity Incentive Plan, increasing the number of shares reserved for issuance by 300,000 at the annual meeting on May 21, 2025.

Aytu BioPharma announces a profitable third quarter in fiscal year 2025, driven by revenue growth in its ADHD and Pediatric portfolios and strategic cost reductions.

Aytu BioPharma announces a profitable second quarter for fiscal year 2025, driven by significant growth in its Pediatric Portfolio and overall prescription increases.

Aytu BioPharma has scheduled a court hearing for January 13, 2025, to approve a settlement of derivative claims related to alleged breaches of fiduciary duty.

Aytu BioPharma announced its first quarter fiscal 2025 results, reporting net income of $1.5 million and the appointment of Ryan Selhorn as Chief Financial Officer.

Aytu BioPharma has entered into an exclusive agreement with Lupin Pharma Canada to commercialize its Adzenys XR-ODT and Cotempla XR-ODT ADHD medications in Canada.

Aytu BioPharma's fiscal year 2024 saw a strategic shift towards its prescription (Rx) segment, resulting in improved adjusted EBITDA despite a decrease in overall revenue due to the divestiture of its Consumer Health segment.

Aytu BioPharma has divested its Consumer Health business to a private e-commerce company, allowing the company to focus on its prescription pharmaceutical segment.

Aytu BioPharma successfully held its 2024 annual meeting, electing all incumbent directors and approving the appointment of Grant Thornton LLP as its independent auditor.

Aytu BioPharma successfully refinanced its term loan and extended its revolving credit facility, achieving more favorable terms and reducing interest expenses.

Aytu BioPharma's ADHD portfolio saw a 49% revenue increase in Q3 2024, contributing to positive adjusted EBITDA and a strategic shift towards the Rx segment.

Aytu BioPharma reports a significant increase in ADHD portfolio revenue and its first-ever positive operating income in the second quarter of fiscal year 2024, driven by strategic focus on its Rx segment.